On Tuesday, Shares of Chesapeake Energy Corporation (NYSE:CHK), lost -4.87% to $8.21, as oil prices hit a six-year low Tuesday, reacting to the devaluation of the Chinese yuan and a report of higher Iranian oil production.
West Texas Intermediate, the benchmark U.S. crude, for September delivery closed at $43.08 per barrel on the New York Mercantile Exchange, down $1.88, the lowest since 2009.
Chesapeake Energy Corporation produces oil and natural gas through acquisition, exploration, and development of from underground reservoirs in the United States.
Shares of Intrexon Corporation (NYSE:XON), declined -15.17% to $48.93, during its last trading session.
Intrexon Corporation declared its second quarter and first half results for 2015.
Business Highlights and Recent Developments:
- During the second quarter, Intrexon’s exclusive partnershipand license agreement with the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, to develop and commercialize chimeric antigen receptor T-cell (CAR-T) cancer therapies became effective, resulting in the receipt of $115 million, 50% of which is payable to ZIOPHARM Oncology, Inc., as an upfront fee in July 2015. Focused on the generation of leading-edge products that empower the immune system in a regulated manner, the collaboration’s first two CAR-T targets of interest have been selected and Intrexon has initiated research and development efforts on these programs;
- Granted a special stock dividend of ZIOPHARM Oncology, Inc. (ZIOP) shares owned by Intrexon to its shareholders valued at about $172 million at the time of distribution. Holders of Intrexon common stock received 0.162203 shares of ZIOPHARM common stock at $9.67 per share with respect to each outstanding share of Intrexon common stock they owned;
- Declared a Cooperative Research and Development Agreement with the National Cancer Institute (NCI). The principal aim is to develop and evaluate improved adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes with naturally occurring endogenous anti-tumor activity combined with the RheoSwitch Therapeutic System® for introducing spatially and temporally controlled interleukin-12 (IL-12) expression in ACT/PBL/IL-12 for the treatment of patients with solid tumor malignancies.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
Finally, Michael Kors Holdings Limited (NYSE:KORS), ended its last trade with 0.18% gain, and closed at $45.37.
Michael Kors Holdings declared its financial results for the fiscal 2016 first quarter ended June 27, 2015.
For the first quarter ended June 27, 2015:
- Total revenue raised 7.3% to $986.0 million from $919.2 million in the first quarter of fiscal 2015. On a constant currency basis, total revenue raised 13.4%.
- Retail net sales raised 9.0% to $523.3 million driven by 107 net new store openings since the end of the first quarter of fiscal 2015 and e-commerce sales from our North American digital flagships, partially offset by a 9.5% decrease in comparable store sales. On a constant currency basis, retail net sales grew 16.0%, and comparable store sales reduced 5.0%. Wholesale net sales raised 4.2% to $424.0 million and on a constant currency basis, wholesale net sales grew 9.7%. Licensing revenue raised 20.5% to $38.7 million.
- Total revenue in North America raised 1.2% to $727.3 million on a stated basis and raised 1.9% on a constant currency basis. European revenue grew 16.9% to $216.8 million on a stated basis, and grew 42.2% on a constant currency basis. Revenue in Japan raised 32.7% to $19.6 million on a stated basis, and raised 57.4% on a constant currency basis.
- Gross profit raised 5.6% to $603.6 million, and as a percentage of total revenue was 61.2%. Gross profit margin was reduced by about 63 basis points due to the change in foreign currency exchange rates. This compares to 62.2% in the first quarter of fiscal 2015.
Michael Kors Holdings Limited engages in the design, marketing, distribution, and retailing of branded women’s apparel and accessories, and men’s apparel. The company operates in three segments: Retail, Wholesale, and Licensing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
